300 related articles for article (PubMed ID: 32445613)
21. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
Back D; Belperio P; Bondin M; Negro F; Talal AH; Park C; Zhang Z; Pinsky B; Crown E; Mensa FJ; Marra F
J Viral Hepat; 2019 Aug; 26(8):951-960. PubMed ID: 30977945
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Toyoda H; Chayama K; Suzuki F; Sato K; Atarashi T; Watanabe T; Atsukawa M; Naganuma A; Notsumata K; Osaki Y; Nakamuta M; Takaguchi K; Saito S; Kato K; Pugatch D; Burroughs M; Redman R; Alves K; Pilot-Matias TJ; Oberoi RK; Fu B; Kumada H
Hepatology; 2018 Feb; 67(2):505-513. PubMed ID: 28865152
[TBL] [Abstract][Full Text] [Related]
25. Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis.
Lu M; Rupp LB; Melkonian C; Trudeau S; Daida YG; Schmidt MA; Gordon SC
Adv Ther; 2024 Feb; 41(2):744-758. PubMed ID: 38169058
[TBL] [Abstract][Full Text] [Related]
26. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.
Lampertico P; Carrión JA; Curry M; Turnes J; Cornberg M; Negro F; Brown A; Persico M; Wick N; Porcalla A; Pangerl A; Crown E; Larsen L; Yu Y; Wedemeyer H
J Hepatol; 2020 Jun; 72(6):1112-1121. PubMed ID: 32061651
[TBL] [Abstract][Full Text] [Related]
27. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
[TBL] [Abstract][Full Text] [Related]
28. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.
Ruwayni AA; AlObary EE; Alyahya KM
Saudi Med J; 2024 Jan; 45(1):34-39. PubMed ID: 38220241
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
Lawitz E; Flisiak R; Abunimeh M; Sise ME; Park JY; Kaskas M; Bruchfeld A; Wörns MA; Aglitti A; Zamor PJ; Xue Z; Schnell G; Jalundhwala YJ; Porcalla A; Mensa FJ; Persico M
Liver Int; 2020 May; 40(5):1032-1041. PubMed ID: 31821716
[TBL] [Abstract][Full Text] [Related]
31. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
[TBL] [Abstract][Full Text] [Related]
32. Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.
Klinker H; Naumann U; Rössle M; Berg T; Bondin M; Lohmann K; Koenig B; Zeuzem S; Cornberg M
Liver Int; 2021 Jul; 41(7):1518-1522. PubMed ID: 33966349
[TBL] [Abstract][Full Text] [Related]
33. Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal.
Vera J; Gomes A; Póvoas D; Seixas D; Maltez F; Pedroto I; Maia L; Mota M; Vieira MJ; Manata MJ; Ferreira P; Lino S; Pereira Guedes T; Barradas V; Marques N
Acta Med Port; 2024 May; 37(5):323-333. PubMed ID: 38325411
[TBL] [Abstract][Full Text] [Related]
34. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
Gane E; de Ledinghen V; Dylla DE; Rizzardini G; Shiffman ML; Barclay ST; Calleja JL; Xue Z; Burroughs M; Gutierrez JA
J Viral Hepat; 2021 Nov; 28(11):1635-1642. PubMed ID: 34448313
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Papaluca T; Roberts SK; Strasser SI; Stuart KA; Farrell G; MacQuillan G; Dore GJ; Wade AJ; George J; Hazeldine S; O'Beirne J; Wigg A; Fisher L; McGarity B; Sawhney R; Sinclair M; Thomas J; Valiozis I; Weltman M; Wilson M; Woodward A; Ahlenstiel G; Haque M; Levy M; Prewett E; Sievert W; Sood S; Tse E; Valaydon Z; Bowden S; Douglas M; New K; O'Keefe J; Hellard M; Doyle J; Stoove M; Thompson AJ
Clin Infect Dis; 2021 Nov; 73(9):e3288-e3295. PubMed ID: 32887983
[TBL] [Abstract][Full Text] [Related]
37. Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
Flamm S; Mutimer D; Asatryan A; Wang S; Rockstroh J; Horsmans Y; Kwo PY; Weiland O; Villa E; Heo J; Gane E; Ryder SD; Welzel TM; Ruane PJ; Agarwal K; Ng TI; Xue Z; Lovell SS; Krishnan P; Kopecky-Bromberg S; Trinh R; Mensa FJ; Wyles DL
J Viral Hepat; 2019 Mar; 26(3):337-349. PubMed ID: 30421537
[TBL] [Abstract][Full Text] [Related]
38. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
[TBL] [Abstract][Full Text] [Related]
39. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Zamor PJ; Brown A; Dylla DE; Dillon JF; Luetkemeyer AF; Feld JJ; Mutimer D; Ghalib R; Crown E; Lovell SS; Hu Y; Moreno C; Nelson DR; Colombo M; Papatheodoridis G; Rockstroh JK; Skoien R; Lawitz E; Jacobson IM
Am J Gastroenterol; 2021 Sep; 116(9):1896-1904. PubMed ID: 34465693
[TBL] [Abstract][Full Text] [Related]
40. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.
Brown A; Welzel TM; Conway B; Negro F; Bräu N; Grebely J; Puoti M; Aghemo A; Kleine H; Pugatch D; Mensa FJ; Chen YJ; Lei Y; Lawitz E; Asselah T
Liver Int; 2020 Apr; 40(4):778-786. PubMed ID: 31568620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]